Oxurion NV (FRA:TG40) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 13, 2026)


What is Oxurion NV Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Oxurion NV's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

FRA:TG40 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Oxurion NV's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxurion NV Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Oxurion NV's Margin of Safety % (DCF Dividends Based) falls into.


Oxurion NV Business Description

Other Exchanges TG40:GermanyOXUR:Belgium
Address Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.